Table 2 Overview of the therapy all patients received during the three treatment time periods
Therapy (all patients n = 1108) | |||||
|---|---|---|---|---|---|
Time period I | Time period II | Time period III | p-value* | All time periods | |
(1986–1994) | (1995–2003) | (2004 – 2013) | |||
Any therapy | 341 (93.9%) | 331 (94.8%) | 382 (96.5%) | 0.260 | 1054 (95.1%) |
Any operation | 332 (91.5%) | 318 (91.1%) | 347 (87.6%) | 0.148 | 996 (90.0%) |
D2 gastrectomy | 178 (53.3%) | 196 (61.6%) | 231 (66.8%) | 0.001 | 605 (60.7%) |
30d mortality | 3 (1.7%) | 2 (1,0%) | 7 (3.0%) | 0.314 | 12 (2.0%) |
90d mortality | 8 (4.5%) | 9 (4.6%) | 16 (6.9%) | 0.456 | 33 (5.5%) |
tumor-free | 157 (88.2%) | 184 (93.9%) | 219 (94.8%) | 0.085 | 560 (92.6%) |
Thereof w/o 30d-mortality | 155 (98.7%) | 182 (98.9%) | 213 (97.3%) | 0.390 | 550 (98.2%) |
Chemotherapy | 45 (12.4%) | 60 (17.2%) | 211 (53.3%) | <0.001 | 316 (28.5%) |
5-FU | 40 (11.0%) | 45 (12.9%) | 3 (0.8%) | <0.001 | 88 (7.9%) |
Combination* | 5 (1.4%) | 4 (1.1%) | 101 (25.5%) | <0.001 | 110 (9.9%) |
Combination + antibody** | 0 (0%) | 0 (0%) | 16 (4%) | <0.001 | 16 (1.4%) |
Chemoregimen undocumented | 0 (0%) | 11 (3.2%) | 91 (8.2%) | <0.001 | 102 (9.2%) |
Perioperative chemotherapy in curative treated and RO patients (N = 550) | |||||
Patients | 155 | 182 | 213 | 550 | |
Perioperative therapy | 0 (0%) | 0 (0%) | 64 (30.0%) | <0.001 | 65 (11.6%) |
No perioperative therapy | 155 (100%) | 182 (100%) | 148 (70.0%) | <0.001 | 485 (88.4%) |